Evidence map›Paper›PMID 40165108›Full record

ArticleBMC cancer2025

Development of a m6A- and ferroptosis-related LncRNA signature for forecasting prognosis and treatment response in cervical cancer.

Kaiting Wen, Lili Wang, Huancheng Su, Lijun Yu, Sanyuan Zhang, Meiyan Wei, Yaling Wang, Le Zhao, Yan Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kaiting WenDepartment of Gynecology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China.
Lili WangDepartment of Gynecology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China.
Huancheng SuDepartment of Gynecology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China.
Lijun YuDepartment of Gynecology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China. yulijun100@163.com.
Sanyuan ZhangDepartment of Gynecology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China. zsyprofessor@aliyun.com.
Meiyan WeiDepartment of Gynecology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China.
Yaling WangDepartment of Gynecology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China.
Le ZhaoDepartment of Gynecology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China.
Yan GuoDepartment of Gynecology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundN6-methyladenosine (m6A) and ferroptosis are involved in the development and prognosis of various cancers via long noncoding RNAs (lncRNAs). This study aimed to investigate the cervical cancer subtypes based on m6A-and ferroptosis-related lncRNAs (mfrlncRNAs) and to construct a mfrlncRNA signature to predict cervical cancer prognosis and treatment response.

methodsmfrlncRNA-related cervical cancer subtypes were identified based on public datasets, and their differences in terms of prognosis, immune cell infiltration, and biological mechanisms were compared. Moreover, prognosis-related mfrlncRNAs were identified to construct a prognostic signature. A nomogram was constructed based on the independent prognostic factors. Immune characteristics, immunotherapy response predictions, and drug sensitivity analyses were performed for both risk groups. Furthermore, quantitative PCR was performed to validate the differential expression of the signature mfrlncRNAs in clinical samples.

resultsIn total, 549 differentially expressed mfrlncRNAs were identified between cervical cancer and normal samples. Two mfrlncRNA-related cervical cancer subtypes that exhibited distinct prognoses, immune characteristics, and biological mechanisms were identified. A prognostic signature was developed using six prognostic mfrlncRNAs: AC016065.1, AC096992.2, AC119427.1, AC133644.1, AL121944.1, and FOXD1_AS1. This prognostic signature exhibited high performance in predicting the prognosis of cervical cancer. Moreover, RiskScore and stage were identified as independent prognostic factors, and a nomogram was constructed to accurately forecast overall survival. Furthermore, patients in the low-risk group had a more active immunotherapy response and were more sensitive to chemotherapeutic drugs such as imatinib. Upregulated expression of AC119427.1, AC133644.1, AL121944.1, and FOXD1_AS1 was observed in the tumor samples.

conclusionsThe six-mfrlncRNA signature is a new biomarker for forecasting prognosis and treatment response in cervical cancer.

Indexed as

AdenosineBiomarkers, TumorFerroptosisRNA, Long NoncodingUterine Cervical NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansNomogramsPrognosisAdenosineBiomarkers, TumorN-methyladenosineRNA, Long NoncodingCervical cancerFerroptosisLong non-coding RNAN6-methyladenosinePrognostic signature

Identifiers

PMID40165108
PMCPMC11959838

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.